3 withdrawn, 1 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Withdrawn 3, Completed 1 |
Follow Continuous glucose monitoring system: new trials by email Literature Review of Continuous glucose monitoring system trials Research Report on Continuous glucose monitoring system
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes 12-day intervention with sensor-augmented pump therapy, 12-day intervention with single-hormone closed-loop strategy, Insulin pump - Type 1 Diabetes | Phase 2 | Completed | Institut de Recherches Cliniques de Montreal | 36 | 2019-01-24 | 2020-06-11 |
| Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels Insulin pump, Continuous glucose monitoring system, 11-hour intervention with the single-hormone artificial pancreas - Type 1 Diabetes Mellitus | Phase 2 | Withdrawn | Institut de Recherches Cliniques de Montreal | 2018-04-01 | 2018-04-27 | |
| Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes 5-day intervention with single-hormone closed-loop strategy, 5-day intervention with sensor-augmented pump therapy, Insulin pump - Type 1 Diabetes | Phase 2 | Withdrawn | Institut de Recherches Cliniques de Montreal | 2018-03-01 | 2018-01-31 | |
| Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes 15-week intervention with sensor-augmented pump, 15-week intervention with single-hormone closed-loop, 15-week intervention with dual-hormone closed-loop - Type 1 Diabetes | Phase 2 | Withdrawn | Institut de Recherches Cliniques de Montreal | 2019-07-23 |
Diabetes Mellitus, Type 1 (4) · Insulin Resistance (4) · Hypoglycemia (3)
Institut de Recherches Cliniques de Montreal (4)
Canada (2)